Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
A. J. Gerard Jansen, Vickie McDonald, Adrian Newland, Mervyn Morgan, Mieke Bastiaanse, Koo Wilson, Daniel Eriksson, Emma Geldman, Owen Daykin-Pont, Samantha Prince & Jaap Jan Zwaginga. (2023) Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study). Hematology 28:1.
Read now
Read now
Alessandro Lucchesi, Barbara Lovrencic, Vickie McDonald, Adrian Newland, Mervyn Morgan, Daniel Eriksson, Koo Wilson, Giulio Giordano, Giuseppe Carli, Emma Geldman, Owen Daykin-Pont, Samantha Prince & Mariasanta Napolitano. (2023) Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort. Hematology 28:1.
Read now
Read now
Kristin T Ansteatt, Chanel J Unzicker, Marsha L Hurn, Oluwaseun O Olaiya, Diane J Nugent & Michael D Tarantino. (2020) The Need for Comprehensive Care for Persons with Chronic Immune Thrombocytopenic Purpura. Journal of Blood Medicine 11, pages 457-463.
Read now
Read now
Patrick Trotter & Quentin A Hill. (2018) Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Related Outcome Measures 9, pages 369-384.
Read now
Read now
Prina Z. Donga, Sara P. Bilir, Gregg Little, Tim Babinchak & Julie Munakata. (2017) Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura. Journal of Medical Economics 20:11, pages 1200-1206.
Read now
Read now
Abdulgabar Salama. (2017) Emerging drugs for immune thrombocytopenia (ITP). Expert Opinion on Emerging Drugs 22:1, pages 27-38.
Read now
Read now
Robert Deuson, Mark Danese, Susan D. Mathias, Marieke Schoonen & Jon Fryzek. (2012) The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim. Journal of Medical Economics 15:5, pages 956-976.
Read now
Read now
Articles from other publishers (9)
Axel Rüfer & Deirdra R. Terrell. (2023)
Burden of immune thrombocytopenia (
ITP
): Special considerations for refractory
ITP
. British Journal of Haematology 203:1, pages 79-85.
Crossref
Crossref
Mingjun Rui, Yingcheng Wang, Zhengyang Fei, Ye Shang, Aixia Ma & Hongchao Li. (2021) Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China. Frontiers in Medicine 8.
Crossref
Crossref
Nichola Cooper, Alexandra Kruse, Caroline Kruse, Shirley Watson, Mervyn Morgan, Drew Provan, Waleed Ghanima, Donald M. Arnold, Yoshiaki Tomiyama, Cristina Santoro, Marc Michel, Serge Laborde, Barbara Lovrencic, Ming Hou, Tom Bailey, Gavin Taylor‐Stokes, Jens Haenig & James B. Bussel. (2020)
Immune thrombocytopenia (
ITP
)
World Impact Survey
(
I‐WISh
): Impact of
ITP
on health‐related quality of life
. American Journal of Hematology 96:2, pages 199-207.
Crossref
Crossref
David J. Kuter, Donald M. Arnold, Francesco Rodeghiero, Ann Janssens, Dominik Selleslag, Robert Bird, Adrian Newland, Jiri Mayer, Kejia Wang & Robert Olie. (2020) Safety and efficacy of self‐administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. American Journal of Hematology 95:6, pages 643-651.
Crossref
Crossref
Julie Pell, Rosemary Greenwood, Jenny Ingram, Katherine Wale, Ian Thomas, Rebecca Kandiyali, Andrew Mumford, Andrew Dick, Catherine Bagot, Nichola Cooper, Quentin Hill & Charlotte Ann Bradbury. (2018) Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. BMJ Open 8:10, pages e024427.
Crossref
Crossref
David J. Kuter, Cynthia Macahilig, Kelly M. Grotzinger, Sara A. Poston, Peter Feng Wang, Katie L. Dawson & Melea Ward. (2015) Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. International Journal of Hematology 101:3, pages 255-263.
Crossref
Crossref
Dawn Lee, Patrick Thornton, Alexander Hirst, Lucie Kutikova, Robert Deuson & Nic Brereton. (2013) Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland. Applied Health Economics and Health Policy 11:5, pages 457-469.
Crossref
Crossref
C C Chang, H C Chang, C H Wu, C Y Chang, C C Liao & T L Chen. (2013) Adverse postoperative outcomes in surgical patients with immune thrombocytopenia. British Journal of Surgery 100:5, pages 684-692.
Crossref
Crossref
Mehdi Khellaf, Jean-Gabriel Le Moine, Priscille Poitrinal, Camille Francesconi, Albert Haddad, Philippe Bierling, Marc Michel, Laurent Eckert, Robert Launois & Bertrand Godeau. (2010) Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Annals of Hematology 90:4, pages 441-446.
Crossref
Crossref